20 November 2023 - NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.

Recent breakthroughs in our understanding of the disease have begun to shed light on its complex nature and new treatments have begun to emerge including (disease-modifying dementia treatments). These treatments aim to alter the course of disease progression and reduce its substantial impact.

Read NICE press release